Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of aescin and salt thereof in preparing medicine for treating cataracts

A escin and cataract technology, which is applied in drug delivery, drug combination, and pharmaceutical formula, etc., can solve the problems of complex pathogenesis, different treatment methods, and no cataract, etc., and achieve significant curative effect, good safety, and less irritation Effect

Active Publication Date: 2018-02-23
WUHAN AIMIN PHARMA
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, because the pathogenesis of cataract is more complicated than that of fundus disease, the treatment methods are obviously different from those of fundus disease (such as cataract).
Therefore, it is impossible for those skilled in the art to think that sodium aescinate can also treat cataract on the basis of CN 102920722 A, and so far, there are no reports of other aescin and its salts for treating cataract

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of aescin and salt thereof in preparing medicine for treating cataracts
  • Application of aescin and salt thereof in preparing medicine for treating cataracts

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1 7

[0020] Example 1 Efficacy Test of Aescin and Its Salts in Treating Cataracts

[0021] Test drugs: 50% D-galactose solution, Baineiting eye drops (0.05mg / ml), lysine aescin eye drops (0.5%, 0.8%, 1.2%).

[0022] Take 120 3-week-old pups, half male and half male, and randomly divide them into 6 groups, 20 rats in each group, namely: blank group, model group, positive control group, lysine aescin high, medium and low dose groups . Observing with a slit microscope before administration, those with transparent crystals are available for use; Modeling: Animals are injected intraperitoneally with 50% D-galactose solution 15g / kg every day, divided into two injections, with an interval of more than 4 hours, and continuously injected for 14 days. For animals in the blank group Normal saline (0.1mL / eye) was instilled in both eyes. The model group was given 1 drop of normal saline / eye, the positive control group was given 1 drop / eye of Baineiting eye drops, and the high, middle and low ...

Embodiment 2 7

[0028] The eye irritation test of embodiment 2 aescin and its salt

[0029] Test drug:

[0030] 0.8% Lysine Aescin Eye Drops: Take 0.8g of lysine aescin, 1g of sodium chloride, 0.5g of borate, dissolve it in water for injection to 100g, filter it, and prepare it now after steam sterilization use.

[0031] 1.2% Lysine Aescin Eye Drops: Take 1.2g of lysine aescin, 1g of sodium chloride, 0.5g of borate, dissolve it in water for injection to 100g, filter it, and make it now after steam sterilization use.

[0032] 0.8% Sodium Aescinate Eye Drops: Take 0.8g of Sodium Aescinate, 1g of Sodium Chloride, and 0.5g of Borate, dissolve it in water for injection to 100g, filter it, and prepare it for immediate use after steam sterilization.

[0033] 1.2% Sodium Aescinate Eye Drops: Take 1.2g of Sodium Aescinate, 1g of Sodium Chloride, and 0.5g of Borate, dissolve it in water for injection to 100g, filter it, and prepare it for immediate use after steam sterilization.

[0034] 16 healthy...

Embodiment 3

[0038] Example 3 typical case

[0039]Wang Moumou, female, 73 years old, was first diagnosed in November 2015. Complaints of blurred vision in both eyes, photophobia, blurred vision. Check: binocular vision 0.13, conjunctiva without hyperemia, cornea transparent, pupil equal in size and round, good light reflection, iris and ciliary body without hyperemia, lens is off-white with different turbidity, and vitreous body is not turbid. There was no abnormality in fundus peeping, and it was diagnosed as the terminal stage of senile cataract in both eyes. After 21 days of treatment with lysine aescin eye drops, the binocular vision improved to 0.5, and 30 days was a course of treatment, and the binocular vision improved to 0.7. Slit-lamp examination after pupil dilation showed that the lens opacity disappeared, and the vision was stable after 6 months of follow-up.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Mild irritantaaaaaaaaaa
Login to View More

Abstract

The invention discloses application of aescin and salt thereof in preparing medicine for treating cataracts, and belongs to the field of pharmacy. Through a rat cataract model built by injecting galactose, the treatment effect of aescin and salt thereof on rat cataracts is evaluated by adopting a phacoscotasmus grading method; the result shows that aescin and salt thereof can significantly lower the phacoscotasmus grade, and thus it is verified that aescin and salt thereof have the effect of delaying the formation and development of rat cataracts.

Description

technical field [0001] The invention relates to the new pharmaceutical application of aescin and its salt, especially the new application in the preparation of medicines for treating cataract. The invention also relates to an eye drop for treating cataract, belonging to the pharmaceutical field. Background technique [0002] Cataract is a common eye disease and an important cause of blindness. At present, with the continuous acceleration of the aging population in my country, the incidence of cataract is also increasing significantly. The occurrence of cataract can be caused by factors such as aging, heredity, immunity, metabolic abnormality, radiation, poisoning, trauma, and local nutrition. The main physical and chemical process of cataract is the formation of protein polymers to cause lens opacity. Because the mechanism of cataract formation is very complicated, it is currently believed that agglutination and syneresis can lead to lens opacity, so surgical treatment is r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61K9/08A61P27/12
CPCA61K9/0048A61K9/08A61K31/704
Inventor 石召华叶利春张洋关小羽吴灯张晓存刘享平
Owner WUHAN AIMIN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com